AR044496A1 - N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND ITS EMPLOYMENT AS MEDICATIONS - Google Patents

N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND ITS EMPLOYMENT AS MEDICATIONS

Info

Publication number
AR044496A1
AR044496A1 ARP040100469A ARP040100469A AR044496A1 AR 044496 A1 AR044496 A1 AR 044496A1 AR P040100469 A ARP040100469 A AR P040100469A AR P040100469 A ARP040100469 A AR P040100469A AR 044496 A1 AR044496 A1 AR 044496A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
mean
links
aryl
Prior art date
Application number
ARP040100469A
Other languages
Spanish (es)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32841665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR044496A1 publication Critical patent/AR044496A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

N-arilheterociclos substituidos, sus sales fisiológicamente tolerables y derivados fisiológicamente funcionales. Los compuestos son útiles como aneroxígenos. Reivindicación 1: Un compuesto de fórmula (1) en la cual R1, R2 significan de manera independiente H, alquilo C1-8, -(CR78R79)o-R12, alcoxi C1-4-alquilo C1-4, ariloxi-alquilo C1-4, alquenilo C3-8, alquinilo C3-8, CO-alquilo C1-8, -CO-(CH2)o-R12, CO-ariloxi-alquilo C1-4, CO-alquenilo C2-8, CO-alquinilo C2-8, COCH-CH(R13), COCC(R14), CO-alquil C1-4-S(O)p-alquilo C1-4, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21)(R22) o CO(C(R23)(R24))sO(R25); o bien R1 y R2, forman junto con el átomo de nitrógeno al cual están unidos, un anillo mono-, bi- o espirocíclico de 4 a 10 eslabones que además del átomo de nitrógeno, puede contener o a 4 heteroátomos adicionales seleccionados del grupo de oxígeno, nitrógeno y azufre, pudiendo el sistema anular heterocíclico estar substituido adicionalmente con F, Cl, Br, CF3, NO2, CN, alquilo C1-6, O-alquilo C1-8, alcoxi C1-4-alquilo C1-4, hidroxi-alquilo C1-4, alquilen C0-8-arilo, oxo, CO(R26), CON(R27)(R28), hidroxi, COO(R29), N(R30)COalquilo C1-6, N(R31)(R32) o SO2CH3; o vale 0, 1, 2, 3, 4, 5 ó 6; p vale 0, 1 ó 2; q, r, s valen de manera independiente 0, 1, 2, 3 ó 4; R13, R14 significan de manera independiente entre sí, un sistema anular aromático de 5 a 10 eslabones, que puede contener 0-2 heteroátomos adicionales del grupo de nitrógeno, oxígeno y azufre, y que puede estar substituido con F, Cl, Br, CF3, NO2, CN, alquilo C1-6 o O-alquilo C1-8; R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32 significan de manera independiente entre sí H o alquilo C1-6; R18 significa H, alquilo C1-6, COalquilo C1-6 o CO(R33); o bien R17 y R18, R21 y R22, R27 y R28, y R31 y R32, significan de manera independiente entre sí, y opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre; R33 significa un sistema anular aromático de 5-10 eslabones, que puede contener 0-2 heteroátomos adicionales del grupo de nitrógeno, oxígeno y azufre, y que puede estar substituido con F, Cl, Br, CF3, NO2, CN, alquilo C1-6 o O-alquilo C1-8; R12 significa OH, O-alquilo C1-6, Oalquilen C0-8-arilo, CN, S-alquilo C1-6, COO(R80), CON(R81)(R93), N(R82)(R83) o anillo mono-, bi- o espirocíclico de 3-12 eslabones, que puede contener uno o varios heteroátomos del grupo de N, O y S, y el anillo de 3-12 eslabones puede contener substituyentes adicionales tales como F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-alquilo C1-6, alcoxi C1-4-alquilo C1-4, S-alquilo C1-6, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, O-cicloalquilo C3-8, cicloalquenilo C3-8, O-cicloalquenilo C3-8, alquinilo C2-6, O-alquilen C0-8-arilo, N(R34)(R35), COCH-CH(R36), (C(R37)(R38))t(R39), CO(C(R37)(R38))t(R39), COalquilo C1-6, COCOOalquilo C1-6, COO(R40), S(O)u(R41) o COOH; t vale 0, 1, 2, 3, 4, 5 ó 6; u vale 0, 1 ó 2; o bien R34, R35, R37, R38 significan de manera independiente entre sí H o alquilo C1-8; R34 y R35, significan opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre, y opcionalmente puede estar substituido con 1 o 2 grupos oxo; R36, R39 significan de manera independiente entre sí cicloalquilo C3-8, un sistema anular aromático de 5-10 eslabones, que puede contener 0-2 heteroátomos adicionales del grupo de nitrógeno, oxígeno y azufre, y que puede estar substituido con F, Cl, Br, CF3, NO2, CN, alquilo C1-6 o O-alquilo C1-8; R40 significa H, alquilo C1-8, alquenilo C2-6 o alquilen C0-8-arilo; R41 significa alquilo C1-8, un sistema anular aromático de 5-10 eslabones, que puede contener 0-2 heteroátomos adicionales del grupo de nitrógeno, oxígeno y azufre, y que puede estar substituido con F, Cl, Br, CF3, NO2, CN, alquilo C1-6 o O-alquilo C1-8; R78, R79 significan de manera independiente entre sí H, alquilo C1-8, hidroxi-alquilo C1-4, OH o alcoxi C1-4-alquilo C1-4; R80, R81, R93 significan de manera independiente entre sí alquilo C1-8, alquenilo C2-6, alquilen C0-8-arilo; R82, R83 significan de manera independiente entre sí H o alquilo C1-6; o bien R82 y R83, significan, opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre, y opcionalmente puede estar substituido con 1 o 2 grupos oxo; R3 significa H, alquilo C1-6; R4, R5 significan, de manera independiente entre sí H, alquilo C1-6, OH, O-alquilo C1-6, O-COalquilo C1-6 o S-alquilo C1-6; o bien R6, R7, R8, R9 significan de manera independiente entre sí H o alquilo C1-8; o bien R6 y R7, y R8 y R9, significan de manera independiente entre sí y opcionalmente, oxo; n, m valen de manera independiente entre sí 0, 1 o 2; A, B, D, G significan de manera independiente entre sí N o C(R42); o bien los grupos A y B, o los grupos D y G son en cada caso C(R42) y forman juntos un radical carbocíclico o heterocíclico de 5 o 6 eslabones, de manera tal que se origina en conjunto un sistema bicíclico; R42 significa H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo C1-6, O-alcoxi C1-4-alquilo C1-4, S-alquilo C1-6, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, O-cicloalquilo C3-8, cicloalquenilo C3-8, O-cicloalquenilo C3-8, alquinilo C2-6, alquilenC0-8-arilo, O-alquilen C0-8-arilo, S-arilo, N(R43)(R44), SO2-CH3, COOH, COO-alquilo C1-6, CON(R45)(R46), N(R47)CO(R48), N(R49)SO2(R50), CO(R51), -(CR84R85)x-O(R86); R43, R44, R45, R46, R47, R49 significan de manera independiente entre sí H o alquilo C1-8; o bien R43 y R44, y R45 y R46, significan de manera independiente entre sí y opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre; R48, R50, R51 significan de manera independiente entre sí H, alquilo C1-8 o arilo; R84, R85 significan de manera independiente entre sí H o alquilo C1-8; R86 significa H, alquilo C1-6 o arilo; x vale 1, 2, 3, 4, 5 ó 6; R10 significa H, alquilo C1-8, alquenilo C3-6 o alquinilo C3-6; X significa N(R52), O, un enlace, C=C, C(R53)(R54), C(R55)(R56)O, CO, C:::C, o un grupo de fórmula -(CR87R88)y-, en la cual uno o más grupos -(CR87R88)- pueden haber sido reemplazados por Y, originándose un radical químicamente con sentido; Y significa O, S o N(R89); R52, R53, R54, R55, R56 significan, de manera independiente entre sí H o alquilo C1-8; R87, R88 significan de manera independiente entre sí H o alquilo C1-4, pudiendo tener R87 y R88 en los grupos "y", en cada caso, los mismos significados o significados diferentes; y vale 2, 3, 4, 5 ó 6; E significa una estructura anular carbo- o heterocíclica, bivalente de 3 a 14 eslabones, y con 0 a 4 heteroátomos del grupo de N, O y S, que opcionalmente puede portar substituyentes del grupo de H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-alquilo C1-6, O-alcoxi C1-4-alquilo C1-4, S-alquilo C1-6, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, O-cicloalquilo C3-8, cicloalquenilo C3-8, O-cicloalquenilo C3-8, alquinilo C2-6, alquilen C0-8-arilo, O-alquilen C0-8-arilo, S-arilo, N(R57)(R58), SO2-CH3, COOH, COO-alquilo C1-6, CON(R59)(R60), N(R61)CO(R62), N(R63)SO2(R64), CO(R65) y que puede ser mono- o bicíclica; R57, R58, R59, R60, R61, R63 significan de manera independiente entre sí H o alquilo C1-8; o bien R57 y R58, y R59 y R60, significan de manera independiente entre sí y opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre; R62, R64, R65 significan de manera independiente entre sí H, alquilo C1-8, arilo; K significa un enlace, O, OCH2, CH2O, S, SO, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, C:::C, C=C un grupo de fórmula -(CR90R91)z-, en donde uno o varios grupos -(CR90R91)- pueden haber sido reemplazados por Z, originándose un radical químicamente con sentido; v vale 1, 2, 3 ó 4; R66, R67, R68, R69, R70 significan de manera independiente entre sí H o alquilo C1-8; Z significa O, S, N(R92), CO, SO o SO2; R90, R91 significan de manera independiente entre sí H, alquilo C1-8, hidroxi-alquilo C1-4, hidroxi, alcoxi C1-4-alquilo C1-4, y pudiendo tener R90 y R91 en los grupos "z" en cada caso los mismos significados o significados diferentes; z vale 2, 3, 4, 5 ó 6; R92 significa H o alquilo C1-8; R11 significa H, alquilo C1-8, alcoxi C1-4-alquilo C1-4, alquenilo C3-8, alquinilo C3-8, un anillo mono-, bi-, tri- o espirocíclico, de 3 a 10 eslabones que puede contener 1, 2, 3 o 4 heteroátomos seleccionados del grupo de oxígeno, nitrógeno y azufre, pudiendo estar el sistema anular substituido adicionalmente con F, Cl, Br, CF3, NO2, CN, alquilo, O-alquilo C1-8, alcoxi C1-4-alquilo C1-4, alquilen C0-8-arilo, oxo, CO(R71), CON(R72)(R73), hidroxi, hidroxi-alquilo C1-4, COO(R74), N(R75)COalquilo C1-6, N(R76)(R77), SO2CH3 o SCF3; R71, R72, R73, R74, R75, R76, R77 significan de manera independiente entre sí y opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre; o bien E, K y R11 forman juntos un triciclo, pudiendo ser los anillos, de manera independiente entre sí, saturados, parcialmente saturados o insaturados, y pudiendo contener en cada caso 3-8 átomos en el anillo; sus N-óxidos y sus sales fisiológicamente tolerables.N-substituted arylheterocycles, their physiologically tolerable salts and physiologically functional derivatives. The compounds are useful as anaerogens. Claim 1: A compound of formula (1) in which R1, R2 independently mean H, C1-8 alkyl, - (CR78R79) or-R12, C1-4 alkoxy-C1-4 alkyl, aryloxy-C1-alkyl 4, C3-8 alkenyl, C3-8 alkynyl, CO- C1-8 alkyl, -CO- (CH2) or -R12, CO-aryloxy-C1-4 alkyl, CO-C2-8 alkenyl, CO-C2 alkynyl 8, COCH-CH (R13), COCC (R14), CO-C 1-4 alkyl-S (O) p-C 1-4 alkyl, CO (C (R15) (R16)) qN (R17) (R18), CO (C (R19) (R20)) rCON (R21) (R22) or CO (C (R23) (R24)) sO (R25); or R1 and R2 together with the nitrogen atom to which they are attached, a mono-, bi- or spirocyclic ring of 4 to 10 links which, in addition to the nitrogen atom, may contain or 4 additional heteroatoms selected from the oxygen group , nitrogen and sulfur, the heterocyclic ring system being able to be additionally substituted with F, Cl, Br, CF3, NO2, CN, C1-6 alkyl, O-C1-8 alkyl, C1-4 alkoxy-C1-4 alkyl, hydroxy- C1-4 alkyl, C0-8-aryl alkylene, oxo, CO (R26), CON (R27) (R28), hydroxy, COO (R29), N (R30) C1-6 alkyl, N (R31) (R32) or SO2CH3; or is worth 0, 1, 2, 3, 4, 5 or 6; p is worth 0, 1 or 2; q, r, s are worth 0, 1, 2, 3 or 4 independently; R13, R14 independently mean to each other, an aromatic ring system of 5 to 10 links, which may contain 0-2 additional heteroatoms of the nitrogen, oxygen and sulfur group, and which may be substituted with F, Cl, Br, CF3 , NO2, CN, C1-6 alkyl or O-C1-8 alkyl; R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32 independently mean each other H or C1-6 alkyl; R18 means H, C1-6 alkyl, CO C1-6 alkyl or CO (R33); or R17 and R18, R21 and R22, R27 and R28, and R31 and R32, mean independently of each other, and optionally together with the nitrogen atom to which they are attached, a ring of 5-6 links that, in addition to the nitrogen atom, it may still contain 0-1 additional heteroatoms of the N- C1-6 alkyl, oxygen and sulfur group; R33 means an aromatic ring system of 5-10 links, which may contain 0-2 additional hetero atoms of the nitrogen, oxygen and sulfur group, and which may be substituted with F, Cl, Br, CF3, NO2, CN, C1- alkyl 6 or O-C1-8 alkyl; R12 means OH, O-C1-6 alkyl, C0-8-alkyl aryl, CN, S-C1-6 alkyl, COO (R80), CON (R81) (R93), N (R82) (R83) or mono ring -, bi- or spirocyclic of 3-12 links, which may contain one or more heteroatoms of the group of N, O and S, and the 3-12 link ring may contain additional substituents such as F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-C1-6 alkyl, C1-4 alkoxy-C1-4 alkyl, S-C1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl , C3-8 O-cycloalkyl, C3-8 cycloalkenyl, C3-8 O-cycloalkenyl, C2-6 alkynyl, C0-8 -alkyl-aryl, N (R34) (R35), COCH-CH (R36), ( C (R37) (R38)) t (R39), CO (C (R37) (R38)) t (R39), CO C1-6 alkyl, COCOO C1-6 alkyl, COO (R40), S (O) or (R41 ) or COOH; t is worth 0, 1, 2, 3, 4, 5 or 6; u is worth 0, 1 or 2; or R34, R35, R37, R38 independently mean each other H or C1-8 alkyl; R34 and R35, optionally mean together with the nitrogen atom to which they are attached, a ring of 5-6 links which, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the N-C1-C-alkyl group 6, oxygen and sulfur, and may optionally be substituted with 1 or 2 oxo groups; R36, R39 independently mean C3-8 cycloalkyl, an aromatic ring system of 5-10 links, which may contain 0-2 additional heteroatoms of the nitrogen, oxygen and sulfur group, and which may be substituted with F, Cl , Br, CF3, NO2, CN, C1-6 alkyl or O-C1-8 alkyl; R40 means H, C1-8 alkyl, C2-6 alkenyl or C0-8-aryl alkylene; R41 means C1-8 alkyl, an aromatic ring system of 5-10 links, which may contain 0-2 additional hetero atoms of the nitrogen, oxygen and sulfur group, and which may be substituted with F, Cl, Br, CF3, NO2, CN, C1-6 alkyl or O-C1-8 alkyl; R78, R79 independently mean each other H, C1-8 alkyl, hydroxy-C1-4 alkyl, OH or C1-4 alkoxy-C1-4 alkyl; R80, R81, R93 independently mean each other C1-8 alkyl, C2-6 alkenyl, C0-8-aryl alkylene; R82, R83 independently mean each other H or C1-6 alkyl; or R82 and R83, optionally, together with the nitrogen atom to which they are attached, a ring of 5-6 links which, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the group of N- C1-6 alkyl, oxygen and sulfur, and may optionally be substituted with 1 or 2 oxo groups; R3 means H, C1-6 alkyl; R4, R5 independently mean H, C1-6 alkyl, OH, O-C1-6 alkyl, O-CO C1-6 alkyl or S-C1-6 alkyl; or R6, R7, R8, R9 independently mean H or C1-8 alkyl; or R6 and R7, and R8 and R9, mean independently of each other and optionally, oxo; n, m are worth 0, 1 or 2 independently of each other; A, B, D, G independently mean each other N or C (R42); Either groups A and B, or groups D and G are in each case C (R42) and together form a carbocyclic or heterocyclic radical of 5 or 6 links, so that a bicyclic system originates together; R42 means H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-C1-6 alkyl, O-C1-4 alkoxy-C1-4 alkyl, S-C1-6 alkyl, C1 alkyl -6, C2-6 alkenyl, C3-8 cycloalkyl, O3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 O-cycloalkenyl, C2-6 alkynyl, C0-8-aryl, O-C0-8 alkylene aryl, S-aryl, N (R43) (R44), SO2-CH3, COOH, COO-C1-6 alkyl, CON (R45) (R46), N (R47) CO (R48), N (R49) SO2 ( R50), CO (R51), - (CR84R85) xO (R86); R43, R44, R45, R46, R47, R49 independently mean each other H or C1-8 alkyl; or R43 and R44, and R45 and R46, mean independently of each other and optionally together with the nitrogen atom to which they are attached, a ring of 5-6 links that, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the N-C1-6 alkyl, oxygen and sulfur group; R48, R50, R51 independently mean each other H, C1-8 alkyl or aryl; R84, R85 independently mean each other H or C1-8 alkyl; R86 means H, C1-6 alkyl or aryl; x is worth 1, 2, 3, 4, 5 or 6; R10 means H, C1-8 alkyl, C3-6 alkenyl or C3-6 alkynyl; X means N (R52), O, a bond, C = C, C (R53) (R54), C (R55) (R56) O, CO, C ::: C, or a group of formula - (CR87R88) and-, in which one or more groups - (CR87R88) - may have been replaced by Y, originating a chemically meaningful radical; Y means O, S or N (R89); R52, R53, R54, R55, R56 means, independently of each other H or C1-8 alkyl; R87, R88 independently mean each other H or C1-4 alkyl, and R87 and R88 may have in the groups "and", in each case, the same different meanings or meanings; and is worth 2, 3, 4, 5 or 6; E means a carbo- or heterocyclic ring structure, bivalent from 3 to 14 links, and with 0 to 4 heteroatoms of the group of N, O and S, which may optionally carry substituents of the group of H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-C1-6 alkyl, O-C1-4 alkoxy-C1-4 alkyl, S-C1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C3 cycloalkyl -8, C3-8 O-cycloalkyl, C3-8 cycloalkenyl, C3-8 O-cycloalkenyl, C2-6 alkynyl, C0-8-aryl alkylene, C0-8-aryl-O-alkylene, S-aryl, N (R57 ) (R58), SO2-CH3, COOH, COO-C1-6 alkyl, CON (R59) (R60), N (R61) CO (R62), N (R63) SO2 (R64), CO (R65) and that it can be mono- or bicyclic; R57, R58, R59, R60, R61, R63 independently mean each other H or C1-8 alkyl; or R57 and R58, and R59 and R60, mean independently of each other and optionally together with the nitrogen atom to which they are attached, a ring of 5-6 links that, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the N-C1-6 alkyl, oxygen and sulfur group; R62, R64, R65 independently mean each other H, C1-8 alkyl, aryl; K means a link, O, OCH2, CH2O, S, SO, SO2, N (R66), N (R67) CO, CON (R68), (C (R69) (R70)) v, CO, C ::: C, C = C a group of formula - (CR90R91) z-, where one or more groups - (CR90R91) - may have been replaced by Z, giving rise to a chemically meaningful radical; v is worth 1, 2, 3 or 4; R66, R67, R68, R69, R70 independently mean each other H or C1-8 alkyl; Z means O, S, N (R92), CO, SO or SO2; R90, R91 independently mean each other H, C1-8 alkyl, hydroxy-C1-4 alkyl, hydroxy, C1-4 alkoxy-C1-4 alkyl, and R90 and R91 may be in groups "z" in each case the same meanings or different meanings; z is worth 2, 3, 4, 5 or 6; R92 means H or C1-8 alkyl; R11 means H, C1-8 alkyl, C1-4 alkoxy-C1-4 alkyl, C3-8 alkenyl, C3-8 alkynyl, a mono-, bi-, tri- or spirocyclic ring, of 3 to 10 links that may contain 1, 2, 3 or 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, the ring system being able to be additionally substituted with F, Cl, Br, CF3, NO2, CN, alkyl, O-C1-8 alkyl, C1- alkoxy 4-C1-4alkyl, C0-8-aryl alkylene, oxo, CO (R71), CON (R72) (R73), hydroxy, hydroxy-C1-4alkyl, COO (R74), N (R75) C1-Calkyl 6, N (R76) (R77), SO2CH3 or SCF3; R71, R72, R73, R74, R75, R76, R77 mean independently of each other and optionally together with the nitrogen atom to which they are attached, a ring of 5-6 links that, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the N- C1-6 alkyl, oxygen and sulfur group; or E, K and R11 together form a tricycle, the rings may be, independently of one another, saturated, partially saturated or unsaturated, and may in each case contain 3-8 atoms in the ring; their N-oxides and their physiologically tolerable salts.

ARP040100469A 2003-02-14 2004-02-16 N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND ITS EMPLOYMENT AS MEDICATIONS AR044496A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10306250A DE10306250A1 (en) 2003-02-14 2003-02-14 Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
AR044496A1 true AR044496A1 (en) 2005-09-14

Family

ID=32841665

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100469A AR044496A1 (en) 2003-02-14 2004-02-16 N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND ITS EMPLOYMENT AS MEDICATIONS

Country Status (29)

Country Link
EP (1) EP1597228A2 (en)
JP (1) JP2006517563A (en)
KR (1) KR20050101215A (en)
CN (1) CN100506792C (en)
AR (1) AR044496A1 (en)
AU (1) AU2004212145B2 (en)
BR (1) BRPI0407504A (en)
CA (1) CA2516118A1 (en)
CO (1) CO5690548A2 (en)
DE (1) DE10306250A1 (en)
EC (1) ECSP055967A (en)
HR (1) HRP20050710A2 (en)
MA (1) MA27735A1 (en)
MX (1) MXPA05008449A (en)
MY (1) MY139102A (en)
NO (1) NO20054220L (en)
NZ (1) NZ541823A (en)
OA (1) OA13027A (en)
PA (1) PA8595901A1 (en)
PE (1) PE20040952A1 (en)
PL (1) PL378065A1 (en)
RS (1) RS20050666A (en)
RU (1) RU2005128551A (en)
TN (1) TNSN05194A1 (en)
TW (1) TW200510297A (en)
UA (1) UA86760C2 (en)
UY (1) UY28186A1 (en)
WO (1) WO2004072025A2 (en)
ZA (1) ZA200506369B (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
ES2327684T3 (en) 2003-07-24 2009-11-02 Euro-Celtique S.A. HETEROARIL-TETRAHIDROPIRIDILO COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF PAIN.
PL1867644T3 (en) * 2003-07-24 2009-10-30 Euro Celtique Sa Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
EP1657240A4 (en) 2003-08-18 2009-04-08 Fujifilm Finechemicals Co Ltd Pyridyltetrahydropyridines, pyridylpiperidines, and process for the production of both
DE10360745A1 (en) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg New amide compounds having MCH antagonist activity and medicaments containing these compounds
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004003812A1 (en) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Aryl-substituted heterocycles, methods of their preparation and their use as pharmaceuticals
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
WO2006010082A1 (en) * 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
WO2006022442A1 (en) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. Novel heterocyclic amide derivatives having dihydroorotate dehydrogenase inhibiting activity
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1799667B1 (en) * 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CA2582327A1 (en) * 2004-10-01 2006-04-13 Takao Suzuki 2-arylcarboxamide-nitrogeneous heterocycle compound
ES2336130T3 (en) 2004-10-18 2010-04-08 Eli Lilly And Company DERIVATIVES 1- (HETERO) ARIL-3-AMINO-PIRROLIDINA FOR USE AS ANGLINGIST OF THE MGLUR3 RECEIVER.
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
DE102004051277A1 (en) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclic carbonyl compounds
US8084492B2 (en) * 2004-11-19 2011-12-27 The New Industry Research Organization Benzofuran compound and pharmaceutical composition containing the same
WO2006074025A1 (en) 2004-12-30 2006-07-13 Janssen Pharmaceutica N.V. Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
WO2006081389A1 (en) 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
JP4870163B2 (en) 2005-09-30 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー Indan derivatives as MCH receptor antagonists
CN102633783A (en) * 2006-02-10 2012-08-15 转化技术制药公司 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
AU2007214708A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
AU2007214710A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
JP5182088B2 (en) * 2006-04-19 2013-04-10 アステラス製薬株式会社 Azole carboxamide derivatives
KR101464385B1 (en) 2006-04-19 2014-11-21 노파르티스 아게 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
UA93548C2 (en) 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
MX2008014290A (en) 2006-05-08 2008-11-26 Ariad Pharma Inc Monocyclic heteroaryl compounds.
BRPI0710328A2 (en) 2006-05-08 2011-08-09 Ariad Pharma Inc compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt, hydrate or other solvate thereof and method for treating cancer in a mammal in need thereof and composition
JP2010500300A (en) 2006-08-08 2010-01-07 サノフィ−アベンティス Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for their preparation, agents containing these compounds, and uses thereof
BRPI0719122A2 (en) 2006-08-24 2013-12-10 Novartis Ag ORGANIC COMPOUNDS
CA2662538A1 (en) * 2006-09-11 2008-03-20 Glaxo Group Limited Azabicyclic compounds as inhibitors of monoamines reuptake
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
PE20080888A1 (en) * 2006-10-18 2008-08-26 Novartis Ag HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1)
WO2008086014A2 (en) * 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
ES2483898T3 (en) 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Piperidine / Piperazine Derivatives
EP2152270B1 (en) * 2007-06-08 2015-03-04 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
JP5443342B2 (en) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Piperidine / piperazine derivatives
TWI452044B (en) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp Morpholine derivative
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
EA017648B1 (en) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
BRPI0816970A2 (en) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
SI2212282T1 (en) * 2007-10-17 2012-01-31 Sanofi Sa Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
DK2212283T3 (en) * 2007-10-17 2011-12-19 Sanofi Sa Substituted N-phenylbipyrrolidine carboxamides and therapeutic use thereof
KR20100082349A (en) * 2007-10-17 2010-07-16 사노피-아벤티스 Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
EP2205558B1 (en) * 2007-10-17 2012-07-25 Sanofi Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
SI2206707T1 (en) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2070916A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
EP2070925A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
EP2070924A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
RU2364597C1 (en) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM
PE20100083A1 (en) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv DRUG COMBINATIONS INCLUDING A DGAT INHIBITOR AND A PPAR AGONIST
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP5547194B2 (en) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 3-Azabicyclo [3.1.0] hexyl derivatives as modulators of metabotropic glutamate receptors
US20110318266A1 (en) * 2008-09-16 2011-12-29 Mccauley John A Phthalimide derivative metabotropic glutamate r4 ligands
JP2012006837A (en) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd 2-indoleacrylamide analogue
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5590040B2 (en) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド Pyrazinopyrazine and derivatives as kinase inhibitors
JP5690277B2 (en) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
AR074466A1 (en) * 2008-12-05 2011-01-19 Sanofi Aventis PIPERIDINE ESPIRO PIRROLIDINONA AND PIPERIDINONA REPLACED AND ITS THERAPEUTIC USE IN DISEASES MEDIATED BY THE MODULATION OF H3 RECEPTORS.
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
JP5642661B2 (en) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Piperidine and pyrrolidine derivatives having NPYY5 receptor antagonistic activity
EP2404896A1 (en) 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Cyclohexane derivative having npy y5 receptor antagonism
CN102439015B (en) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (en) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. 1,2,3-triazolo [4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011060026A1 (en) 2009-11-12 2011-05-19 Jansen Pharmaceutica Nv Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
UA108233C2 (en) 2010-05-03 2015-04-10 Fatty acid amide hydrolysis activity modulators
AR081908A1 (en) * 2010-05-11 2012-10-31 Sanofi Aventis N-HETEROARIL-ESPIROLACTAMA-BIPIRROLIDINAS REPLACED, PREPARATION AND THERAPEUTIC USES OF THE SAME
TW201206939A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
EP2569294B1 (en) * 2010-05-11 2015-03-11 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
UY33469A (en) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING ROAD
JP5852664B2 (en) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
ES2536433T3 (en) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US9051265B2 (en) 2011-06-06 2015-06-09 The Scripps Research Institute N-benzylindole modulators of PPARG
WO2012170554A1 (en) 2011-06-06 2012-12-13 Theodore Mark Kamenecka N-biphenylmethylindole modulators of pparg
US9309227B2 (en) 2011-11-22 2016-04-12 The Scripps Research Institute N-biphenylmethylbenzimidazole modulators of PPARG
WO2013085957A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors
WO2013085954A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
EP2852585A1 (en) * 2012-05-11 2015-04-01 AbbVie Inc. Nampt inhibitors
JP6293770B2 (en) * 2012-11-05 2018-03-14 ナント ホールディングス アイピー，エルエルシー Cyclic sulfonamide-containing derivatives as hedgehog signaling pathway inhibitors
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol Myers Squibb Co DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ME03518B (en) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv COMBINATIONS INCLUDING POSITIVE ALOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR APPLICATIONS
PL3096790T3 (en) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. COMBINATIONS CONTAINING POSITIVE ALLOSTERIC MODULATORS OR ORTOSTERIC AGONISTS OF THE METABOTROPIC GLUTAMINERGIC SUB-TYPE 2 RECEPTOR AND THEIR USE
US10016394B2 (en) 2014-04-16 2018-07-10 The Scripps Research Institute PPARG modulators for treatment of osteoporosis
WO2016008011A1 (en) * 2014-07-16 2016-01-21 Novogen ltd Functionalised and substituted indoles as anti-cancer agents
CN107108581B (en) * 2014-08-21 2020-06-23 百时美施贵宝公司 Tiebacked benzamide derivatives as potent ROCK inhibitors
CA2960274A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
CN108026039A (en) * 2015-08-28 2018-05-11 格兰马克药品股份有限公司 New carbocyclic compound as ROR gamma modulators
RS60825B1 (en) 2016-03-17 2020-10-30 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
CN108815167B (en) * 2017-05-24 2021-04-13 四川晶华生物科技有限公司 Application of compound in preparing medicine for treating tumor
TW202136238A (en) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 ROR[gamma]T inhibitor, preparation method therefor and use thereof
WO2022150962A1 (en) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
CN115160269A (en) * 2021-04-02 2022-10-11 北京大学 Arylcarboxamide derivatives as positive allosteric modulators of NMDAR
MX2024008868A (en) 2022-01-18 2024-09-23 Maze Therapeutics Inc Apol1 inhibitors and methods of use.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (en) 1990-06-18 1992-09-04 Adir NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
DE69522234T2 (en) * 1994-10-26 2002-05-16 Pharmacia & Upjohn Co., Kalamazoo PHENYLOXAZOLIDINONE WITH ANTIMICROBIAL EFFECT
CZ220498A3 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S 1,2,4-thiadiazine and 1,4-thiazine derivatives, preparation and use
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE122009000079I2 (en) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle GLP-1 DERIVATIVES
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
AU757693B2 (en) 1997-07-16 2003-03-06 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (en) 1997-09-19 2000-11-07 Sanofi Synthelabo DERIVATIVES OF CARBOXAMIDOTIAZOLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CA2309121A1 (en) * 1997-11-07 1999-05-20 Schering Corporation Phenyl-alkyl-imidazoles as h3 receptor antagonists
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (en) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Aryl-substituted propanolamine derivatives and their use
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE60017115T2 (en) * 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. AMID DERIVATIVES AND THEIR MEDICAL USE
TR200102911T2 (en) * 1999-04-09 2002-01-21 Astrazeneca Ab Adamantane derivatives.
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002543200A (en) 1999-04-30 2002-12-17 ニューロゲン コーポレイション 9H-pyrimido [4,5-b] indole derivative: CRF1 specific ligand
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
SE9901875D0 (en) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
EP1194146B1 (en) 1999-06-18 2006-07-19 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
CA2378878A1 (en) 1999-07-29 2001-02-08 Jeffrey Thomas Mullaney Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
CA2383781A1 (en) 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
WO2001083451A1 (en) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
JP2004507456A (en) 2000-05-11 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc AGONIST OF THE MELANOCORTIN RECEPTOR
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
WO2002006278A1 (en) * 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
HUP0302966A2 (en) * 2000-07-31 2003-12-29 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor and process for their preparation and pharmaceutical compositions containing them
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Biphenylcarboxamides useful as lipid lowering agents
JP2002338537A (en) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp Amide compounds and their pharmaceutical uses
WO2002098839A1 (en) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides and process for preparation thereof
WO2002098871A1 (en) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Phenylcarboxamides and process for preparation thereof
WO2002099388A2 (en) * 2001-06-07 2002-12-12 Merck & Co., Inc. Benzodiazepine bradykinin antagonists
DE10142734A1 (en) 2001-08-31 2003-03-27 Aventis Pharma Gmbh New (((oxazolylalkyl)-cycloalkyl)-alkyl)-benzoic acid derivatives, are peroxisome proliferator activated receptor agonists or antagonists used e.g. for treating lipid metabolism disorders, type II diabetes, syndrome X and obesity
CA2483306A1 (en) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
JP2004175739A (en) * 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
WO2004072025A2 (en) 2004-08-26
RU2005128551A (en) 2006-02-10
TW200510297A (en) 2005-03-16
RS20050666A (en) 2007-12-31
AU2004212145B2 (en) 2010-06-17
CN100506792C (en) 2009-07-01
UA86760C2 (en) 2009-05-25
PA8595901A1 (en) 2004-09-16
ZA200506369B (en) 2006-07-26
OA13027A (en) 2006-11-10
CA2516118A1 (en) 2004-08-26
BRPI0407504A (en) 2006-02-14
NO20054220L (en) 2005-10-28
ECSP055967A (en) 2006-01-16
PE20040952A1 (en) 2005-02-08
MY139102A (en) 2009-08-28
WO2004072025A3 (en) 2004-12-23
NO20054220D0 (en) 2005-09-12
MXPA05008449A (en) 2006-05-25
CO5690548A2 (en) 2006-10-31
CN1774418A (en) 2006-05-17
KR20050101215A (en) 2005-10-20
UY28186A1 (en) 2004-09-30
MA27735A1 (en) 2006-02-01
EP1597228A2 (en) 2005-11-23
AU2004212145A1 (en) 2004-08-26
PL378065A1 (en) 2006-02-20
DE10306250A1 (en) 2004-09-09
TNSN05194A1 (en) 2007-06-11
HRP20050710A2 (en) 2006-07-31
NZ541823A (en) 2009-01-31
JP2006517563A (en) 2006-07-27

Similar Documents

Publication Publication Date Title
AR050603A1 (en) POLYCLINAL AMINES REPLACED WITH ARILO, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS MEDICATIONS
AR059458A1 (en) ARILDIHYDROISOQUINOLINONES REPLACED WITH AZACICLIL, PROCEDURE FOR PREPARATION AND USE AS MEDICATIONS
AR059522A1 (en) ARILDIHYDROISOQUINOLINAS REPLACED WITH AMINOALCOHOLES, PROCEDURE FOR ITS PREPARATION AND ITS USE AS MEDICATIONS
AR040514A1 (en) REPLACED DIARILIC HETEROCICLES, PROCEDURE FOR THE PREPARATION OF MEDICINES AND THE USE OF COMPOUNDS FOR SUCH PURPOSE
AR059520A1 (en) DERIVATIVES OF SUBSTITUTED AZACICLIL ARYLTIENOPIRIMIDINONES, PROCEDURE FOR PREPARATION, MEDICINES CONTAINING THERAPEUTIC USES AND MCH1R RECEIVER ANTAGONISTS.
AR072707A1 (en) HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
ZA200506369B (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
AR037534A1 (en) DERIVED FROM ADAMANTANO, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR USE IN THERAPY, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH COMPOUND AND SUCH COMPOSITION AND INTERMEDIATE COMPOUNDS
AR047453A1 (en) N - REPLACED CYCLHEXILIMIDAZOLINONES, PROCEDURES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS.
AR059956A1 (en) PHENETALONAMINE DERIVATIVES, PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR053652A1 (en) DERIVATIVES OF INDOL AS PROTEIN QUINASE INHIBITORS. PHARMACEUTICAL COMPOSITIONS
AR048023A1 (en) CETOAMIDS WITH P4 CYCLES AS INHIBITORS OF NS3 SERINA PROTEASA OF HEPATITIS C VIRUS
AR085987A1 (en) TRI- AND TETRACICLIC COMPOUNDS PIRAZOL [3,4-B] PIRIDINE AS ANTINEOPLASIC AGENTS
AR066142A1 (en) IMIDAZOTRIAZINES AND IMIDAZOPIRIMIDINES AS QUINASE INHIBITORS, A COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH THE DISREGULATION OF THE HGF / C-MET SENALIZATION ROUTE
CO5700774A2 (en) TRIAZOL DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASA-1
CO2020001326A2 (en) New heterocyclic compounds as cdk8 / 19 inhibitors
AR046711A1 (en) 5-7-DIAMINOPIRAZOLO [4,3D] PYRIMIDINS AS INHIBITORS OF THE PDE-5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN THE TREATMENT OF HYPERTENSIONS
AR068466A1 (en) CYANOISOQUINOLINE
ECSP066688A (en) CRYSTALLINE POLYMORPH OF A BISULPHATE SALT OF AZEPINOINDOL UNDERIVATES AS PHARMACEUTICAL AGENTS THROMBIN RECEPTOR ANTAGONIST
AR043648A1 (en) BENCENOSULFONAMIDE DERIVATIVES
AR059429A1 (en) COMBINATIONS INVOLVING THE PROTES HCV INHIBITOR (S) AND TREATMENT METHODS RELATED TO THE SAME (S)
AR071763A1 (en) TRISUSTITUTED PIRAZOLS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES OF THE SAME IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
AR044036A1 (en) COMPOUNDS OF PIRAZOLOPIRIMIDINAS AND PIRAZOLOPIRIDINAS AS CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
CO6290767A2 (en) NEW DERIVATIVES OF 5-FENIL-1H-PIRIDIN-2-ONA AND 6-FENIL-2H-PIRIDAZIN-3-0NA AS MODULATORS OF THE ACTIVITY OF THE BTK
AR064345A1 (en) 8-OXOADENINE DERIVATIVES

Legal Events

Date Code Title Description
FB Suspension of granting procedure